繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

下一代ADC要換打法了?不只是換「彈頭」,而是改變整個遞送系統 | Bilingual

2026-11-06 18:02

編者按:2026年第三季度,偶聯藥物領域迎來多項重要進展。兩款靶向B7-H3的抗體偶聯藥物(ADC)在3期研究中取得積極生存數據,已上市ADC和放射性配體療法的應用也向更早治療階段拓展。與此同時,新型載荷、多靶點識別和條件激活技術不斷涌現,多項重磅收購與授權合作反映了行業對這些技術的持續投入。

在這一過程中,遞送系統與載荷是決定ADC能否從分子構想走向可開發候選藥物的關鍵因素之一。藥明康德研發化學服務部(Research Chemistry Services,RCS)構建了覆蓋連接子與載荷合成、分析及純化的一體化技術平臺,為ADC關鍵小分子組件開發提供系統化支持。依託超過10年的項目經驗、580余名專業化學家團隊,以及包含1000余種連接子、30多類抗體連接位點和超過30種新型載荷及其類似物的可定製化體系,RCS能夠幫助合作伙伴高效推進ADC連接子與載荷開發,加速創新偶聯療法從早期研究邁向可開發階段。

臨牀驗證:ADC取得積極生存數據,治療階段進一步前移

多項后期臨牀研究和監管審批為ADC領域帶來了重要進展。其中,兩款靶向B7-H3的ADC在3期研究中均達到總生存期(OS)主要終點,成為9月世界肺癌大會(WCLC)的重要看點。B7-H3是一種在多種腫瘤組織中表達的蛋白,近年來受到ADC研發領域的廣泛關注。9月13日公佈的ARTEMIS-008和TAISHAN-302研究,均針對複發性小細胞肺癌患者,以拓撲替康作為活性對照藥物。

在納入461例患者的ARTEMIS-008研究中,risvutatug rezetecan(Ris-Rez,HS-20093/GSK5764227)達到OS主要終點。治療組中位OS為18.5個月,活性對照組為10.3個月,死亡風險比(HR)為0.46(95% CI:0.35~0.62)。研究同時達到無進展生存期(PFS)等關鍵次要終點。

另一款B7-H3靶向ADC tambotatug pelitecan(Tam-Peli,YL201)在TAISHAN-302研究中也取得積極結果。該研究共納入451例患者,治療組中位OS為13.3個月,活性對照組為9.4個月,HR為0.46(95% CI:0.35~0.62),同樣達到OS主要終點。

兩項隨機對照3期研究為B7-H3靶向ADC治療複發性小細胞肺癌提供了重要臨牀證據,進一步支持了這一靶點的開發潛力。

除了新靶點ADC獲得積極臨牀數據,已經上市的ADC也在向更早治療階段拓展。9月14日,阿斯利康(AstraZeneca)與第一三共(Daiichi Sankyo)公佈Enhertu(trastuzumab deruxtecan)在3期DESTINY-Lung04研究中的詳細數據。該研究評估了Enhertu作為一線療法治療攜帶人表皮生長因子受體2(HER2)基因突變的不可切除局部晚期或轉移性非鱗狀非小細胞肺癌患者的效果。

研究達到PFS主要終點。Enhertu治療組的中位PFS為14.3個月,活性對照組為8.3個月,HR為0.63(95% CI:0.50~0.79)。此前,Enhertu已獲批用於特定既往接受過治療的HER2突變晚期非小細胞肺癌患者。此次研究的積極結果為其進一步拓展至一線治療提供了支持。

7月10日,美國FDA批准擴大Padcev(enfortumab vedotin)與帕博利珠單抗聯合方案在肌層浸潤性膀胱癌圍手術期治療中的適用人群,從不適合接受順鉑治療的患者擴大至所有符合根治性膀胱切除術條件的成年患者。該方案在術前採用新輔助治療,並在膀胱切除術后繼續輔助治療。

此次擴大批准基於納入808例患者的3期KEYNOTE-B15/EV-304研究,結果顯示,該方案在無事件生存期(EFS)和OS方面均取得積極結果。這一進展進一步體現了ADC聯合免疫療法在圍手術期治療中的潛力。

雙特異性ADC也迎來了新的監管進展。7月17日,百利天恆宣佈,其靶向表皮生長因子受體(EGFR)和人表皮生長因子受體3(HER3)的雙特異性ADC倫康依隆妥單抗(iza-bren,商品名:宜澤康)在中國獲批第二項適應症,用於治療既往經PD-1/PD-L1抑制劑聯合含鉑化療治療失敗的複發性或轉移性食管鱗狀細胞癌成人患者。

倫康依隆妥單抗通過同時識別EGFR和HER3,並利用偶聯的拓撲異構酶1(TOPO1)抑制劑載荷發揮抗腫瘤作用。此次獲批基於3期PANKU-Esophagus01研究的積極結果,該研究達到PFS和OS兩項主要終點。

這些進展表明,ADC正在更多癌症類型和治療階段積累臨牀證據,其應用範圍有望進一步拓展。

創新載荷:讓靶向遞送承載更多作用機制

隨着更多ADC進入臨牀應用,如何應對耐藥、擴大治療窗口,成為研發人員關注的重要問題。2026年第三季度,多項收購與授權合作顯示,醫藥企業正在探索新的載荷作用機制,將酶抑制、信號通路阻斷和靶向蛋白降解等策略引入偶聯藥物設計。

7月6日,諾華(Novartis)宣佈擬以11億美元首付款及最高4億美元潛在里程碑付款收購Myricx Bio,獲得其以N-肉豆蔻酰轉移酶抑制劑(NMTi)為載荷的ADC技術平臺。該交易已於8月28日完成。N-肉豆蔻酰轉移酶(NMT)參與蛋白質的脂質修飾,對多種蛋白質的正常功能具有重要作用。與臨牀常用的TOPO1抑制劑載荷不同,NMTi可通過干擾蛋白質修飾過程產生抗腫瘤作用。在臨牀前研究中,Myricx Bio的候選藥物在部分TOPO1抑制劑耐藥模型中仍表現出抗腫瘤活性,為應對現有ADC載荷耐藥提供了新的探索方向。

8月28日,羅氏(Roche)旗下基因泰克(Genentech)與映恩生物(DualityBio)達成全球合作協議,共同開發基於DUPAC新型載荷平臺的下一代ADC。根據協議,映恩生物將獲得4500萬美元首付款,以及超過10億美元的潛在里程碑付款。

DUPAC平臺目前包括DUP5、DUP9和DUP10等多種載荷。其中,DUP5通過抑制真核翻譯起始因子eIF4A,干擾癌細胞內的蛋白質合成;DUP9則是一種魯比卡丁(lurbinectedin)衍生物,可通過干擾RNA聚合酶II介導的轉錄過程誘導DNA損傷。在2025年公佈的臨牀前研究中,基於DUP5或DUP9的ADC在部分對DXd類ADC反應不佳的腫瘤模型中仍表現出抗腫瘤活性。

該平臺還可用於雙載荷ADC開發。例如,映恩生物在2026年美國癌症研究協會(AACR)年會上公佈的DB-1326,將TOPO1抑制劑和DUP9兩種載荷連接至靶向TA-MUC1的抗體,在臨牀前腫瘤模型中取得積極結果。另一項合作則嘗試將靶向信號通路的小分子抑制劑與抗體遞送相結合。

9月3日,和黃醫藥與GSK就HMPL-A830達成授權許可協議,首付款為1.1億美元,另有最高11.85億美元潛在里程碑付款。HMPL-A830將KRAS小分子抑制劑作為載荷,與靶向EGFR的抗體相連接。該藥物旨在利用抗EGFR抗體將KRAS抑制劑遞送至EGFR表達的腫瘤組織,同時發揮對EGFR與KRAS信號通路的阻斷作用。該項目計劃於2026年下半年啟動1期臨牀研究。與傳統細胞毒性ADC不同,這一設計嘗試將抗體靶向作用與小分子通路抑制相結合。

靶向蛋白降解同樣成為偶聯藥物探索的新方向。7月29日,強生(Johnson & Johnson)宣佈完成對Firefly Bio的收購,交易金額為10億美元,獲得其Firelink降解劑抗體偶聯物(DAC)平臺。該平臺利用抗體將具有選擇性的蛋白降解劑遞送至腫瘤細胞,旨在降解疾病相關蛋白,同時減少正常組織暴露。強生計劃利用該技術探索包括KRAS驅動腫瘤在內的實體瘤治療機會。

從NMT抑制劑到KRAS抑制劑,再到蛋白降解劑,偶聯藥物正在嘗試利用靶向遞送技術承載更多類型的藥理機制。

放射性偶聯藥物:治療階段前移,產業整合加速

放射性配體療法是偶聯藥物領域的另一重要方向。與通過化學載荷發揮作用的ADC不同,這類藥物將靶向分子與放射性核素相結合,利用其衰變釋放的輻射殺傷腫瘤細胞。

7月31日,美國FDA批准Pluvicto(lutetium Lu 177 vipivotide tetraxetan)與雄激素受體通路抑制劑(ARPI)聯合,用於治療前列腺特異性膜抗原(PSMA)陽性的轉移性雄激素通路調節初治或敏感性前列腺癌患者,即此前通常所稱的轉移性激素敏感性前列腺癌。此次批准基於納入1144例患者的3期PSMAddition研究。研究達到影像學無進展生存期(rPFS)主要終點,HR為0.72(95% CI:0.58~0.90)。Pluvicto此前已獲批用於治療轉移性去勢抵抗性前列腺癌,此次新適應症將其應用拓展至更早治療階段。

與此同時,放射性配體療法的靶點探索也在向腫瘤微環境延伸。7月20日,Immunome宣佈,其靶向成纖維細胞活化蛋白(FAP)的鑥177放射性配體療法IM-3050在1期臨牀研究中完成首例患者給藥。IM-3050主要靶向腫瘤微環境中的癌症相關成纖維細胞(CAF),旨在將放射性載荷遞送至腫瘤區域,利用β射線的作用影響鄰近癌細胞。該研究將評價其安全性、劑量學、藥代動力學(PK)及初步抗腫瘤活性。

除臨牀進展外,放射性藥物領域在第三季度也迎來了多項重大交易。8月3日,Curium與Lantheus宣佈達成最終合併協議,此次交易涉及的對Lantheus股東的總對價最高約80億美元。雙方計劃通過合併整合放射性診療產品組合、研發管線及全球製造網絡,進一步完善放射性藥物的開發與供應體系。

9月21日,Telix與ITM宣佈達成戰略合併協議。ITM在鑥177、錒225和鋱161等治療性放射性同位素生產方面具有佈局,同時擁有已完成3期臨牀開發的ITM-11等放射性藥物項目。此次擬議合併將整合Telix的臨牀管線和商業化能力,以及ITM的同位素生產與供應資源。

此外,9月22日,博鋭創合(BoomRay)宣佈與諾華達成全球獨家許可協議,涉及一項臨牀前放射性配體療法,首付款與潛在里程碑付款合計最高9億美元。

精準識別與條件激活:如何讓載荷更有效地到達腫瘤?

如果説載荷決定藥物發揮什麼作用,那麼靶點識別、細胞攝取和局部釋放則影響這些作用發生的位置。與傳統單靶點ADC相比,靶向兩種不同抗原的雙特異性ADC有望覆蓋具有不同抗原表達特徵的腫瘤細胞,並通過優化靶點結合與細胞內吞,提高載荷遞送效率。除了前文介紹的倫康依隆妥單抗,更多雙特異性ADC也正在推進臨牀開發。

8月3日,Pathos AI宣佈與康寧傑瑞旗下子公司就JSKN016達成許可協議。根據協議,Pathos AI獲得該藥在大中華區以外的開發和商業化權益,首付款為1.25億美元,另有最高20.93億美元潛在里程碑付款。JSKN016是一款靶向TROP2/HER3的雙特異性ADC,通過糖基位點特異性偶聯形成藥物抗體比(DAR)為4的均一結構,利用雙靶點識別與細胞內吞機制遞送TOPO1抑制劑載荷。該藥物針對三陰性乳腺癌的3期臨牀研究正在進行。

多特異性識別也不限於抗體。9月9日,TwoStep Therapeutics宣佈完成6250萬美元A輪融資,其多特異性多肽偶聯藥物TS-104的IND同時獲得美國FDA許可。TS-104利用能夠結合5種腫瘤相關整合素的多肽作為靶向部分,並連接細胞毒性載荷MMAE。通過同時識別多個腫瘤相關靶點,該藥物旨在降低遞送過程對單一抗原高表達的依賴,提高對腫瘤異質性的適應能力。

與增加識別靶點不同,條件激活技術嘗試利用腫瘤局部的生物學特徵,控制載荷釋放。

9月16日,Avacta公佈FAP激活型多肽偶聯藥物AVA6103的1期FOCUS-01研究初步結果。該藥物利用FAP相關酶活性,在特定環境中觸發exatecan載荷釋放。根據前3個劑量水平、共19例患者的初步安全性及PK數據,研究人員觀察到符合預期的持續釋放特徵,載荷釋放可延續至給藥后數天。這為該平臺的作用機制提供了早期人體研究依據。

這些設計策略説明,偶聯藥物的創新不僅在於選擇合適的靶點,還需要考慮載荷如何進入目標細胞、何時釋放,以及釋放方式能否與藥物作用機制相匹配。隨着偶聯藥物結構日益複雜,連接子、載荷及其他小分子構建模塊的開發也面臨更高要求。除了設計具有特定釋放機制的連接子和新型載荷,研發人員還需要解決複雜分子的合成、結構確認、純化放大以及高活性載荷的安全處理等問題。

藥明康德研發化學服務部構建了覆蓋連接子與載荷合成、分析及純化的一體化技術平臺,為ADC關鍵小分子組件開發提供系統化支持。依託超過10年的項目經驗與580余名專業化學家團隊,RCS已累計交付超過27000種相關化合物,在多類型連接子合成方面積累了豐富實踐經驗。平臺採用模塊化設計理念,建立了包含1000余種連接子、30多類抗體連接位點及超過30種新型載荷及其類似物的可定製化體系。

在載荷與構建模塊方面,RCS覆蓋多類主流細胞毒性分子體系,包括camptothecin類、auristatin類、maytansinoid類、PBD及duocarmycin類等,並建立了完善的構建模塊庫與快速物料調用體系,實現從倉儲到實驗室小於4小時的高效響應。同時,平臺支持毫克級至百克級的靈活合成規模,可滿足不同階段項目需求。配套的先進分析與分離能力涵蓋LC-MS/HPLC、CAD/ELSD檢測、高場核磁(400/500 MHz)、Prep-HPLC-MS及Prep-SFC-MS等技術,可針對穩定性差、紫外響應弱或分離困難的連接子及載荷分子開發專用純化方案,確保結構確證與高回收率。

此外,RCS配備符合規範的高活性化合物操作實驗室,通過隔離器系統、嚴格去污染流程及完善的人員防護與廢棄物管理體系,實現高毒性載荷的安全合規處理。通過將模塊化化學設計、規模化合成能力與高標準安全體系相結合,RCS能夠幫助合作伙伴高效推進ADC連接子與載荷開發,加速創新偶聯療法從早期研究邁向可開發階段。

結語

2026年第三季度,偶聯藥物在臨牀應用和技術創新兩方面取得了重要進展。B7-H3 ADC的積極3期結果,以及ADC和放射性配體療法向更早治療階段拓展,展現了這一領域不斷積累的臨牀證據。與此同時,新型載荷、多靶點識別和條件激活技術,也為未來偶聯藥物的開發提供了更多可能。這些進展對分子設計、合成、分析、製造及臨牀開發提出了新的要求。藥明康德將持續依託其一體化、端到端的CRDMO平臺,支持全球合作伙伴推進創新偶聯藥物研發,為患者帶來更多治療選擇。

Q3 2026 Review of Conjugate Therapeutics

The third quarter of 2026 brought significant advances in conjugate therapeutics. Two B7-H3-targeted antibody-drug conjugates (ADCs) reported positive survival results in Phase 3 trials, while approved ADCs and radioligand therapies continued to move into earlier treatment settings. Meanwhile, novel payloads, multispecific targeting strategies, and conditionally activated drug delivery technologies opened new avenues for conjugate design. Major acquisitions and licensing agreements further underscored the industry's investment in these approaches.

As ADC designs become more complex, linkers and payloads play a critical role in turning molecular concepts into developable drug candidates. WuXi AppTec's Research Chemistry Services (RCS) has established an integrated platform for linker and payload synthesis, analysis, and purification. Backed by more than a decade of project experience, over 580 specialized chemists, and an extensive portfolio of customizable linkers and payloads, RCS helps partners address key development challenges and advance innovative conjugate therapeutics beyond early-stage research.

Clinical Validation: Positive Survival Results and Expansion into Earlier Treatment Settings

The third quarter brought several important clinical and regulatory milestones for ADCs. Among the highlights were two B7-H3-targeted ADCs that met their primary overall survival (OS) endpoints in Phase 3 trials, with results presented at the September World Conference on Lung Cancer (WCLC).

B7-H3, a protein expressed in a range of tumors, has attracted considerable interest as an ADC target. On September 13, results from the ARTEMIS-008 and TAISHAN-302 trials were presented. Both studies evaluated B7-H3-targeted ADCs in patients with relapsed small-cell lung cancer, using topotecan as the active comparator.

In the ARTEMIS-008 trial, which enrolled 461 patients, the investigational ADC risvutatug rezetecan (Ris-Rez, HS-20093/GSK5764227) met its primary OS endpoint. Median OS was 18.5 months in the investigational treatment group versus 10.3 months in the active comparator group, with a hazard ratio (HR) for death of 0.46 (95% CI: 0.35–0.62). The study also met key secondary endpoints, including progression-free survival (PFS).

Another B7-H3-targeted ADC, tambotatug pelitecan (Tam-Peli, YL201), delivered positive results in the TAISHAN-302 trial. Among 451 enrolled patients, median OS was 13.3 months in the investigational treatment group versus 9.4 months in the active comparator group, with an HR of 0.46 (95% CI: 0.35–0.62). This trial also met its primary OS endpoint.

Together, these randomized Phase 3 studies provide important clinical evidence supporting further development of B7-H3-targeted ADCs for relapsed small-cell lung cancer.

Beyond progress with emerging ADC targets, established therapies are also being evaluated earlier in the treatment course.

On September 14, AstraZeneca and Daiichi Sankyo announced detailed results from the Phase 3 DESTINY-Lung04 trial of Enhertu (trastuzumab deruxtecan). The study evaluated Enhertu as a first-line treatment for patients with unresectable locally advanced or metastatic nonsquamous non-small-cell lung cancer harboring HER2 mutations. The trial met its primary PFS endpoint. Median PFS was 14.3 months with Enhertu versus 8.3 months with the active comparator, with an HR of 0.63 (95% CI: 0.50–0.79). Enhertu had previously been approved for certain patients with previously treated HER2-mutant advanced non-small-cell lung cancer. These positive findings support the potential use of Enhertu in the first-line setting.

On July 10, the U.S. FDA expanded the approved perioperative use of Padcev (enfortumab vedotin) in combination with pembrolizumab for muscle-invasive bladder cancer. The expanded indication covers adults eligible for radical cystectomy, regardless of cisplatin eligibility.

The regimen includes neoadjuvant treatment before surgery, followed by adjuvant treatment after radical cystectomy. The expanded approval was based on results from the Phase 3 KEYNOTE-B15/EV-304 trial, which enrolled 808 patients and demonstrated positive results for both event-free survival (EFS) and OS. This milestone further highlights the potential of combining ADCs with immunotherapy in the perioperative setting.

Bispecific ADCs also reached a new regulatory milestone. On July 17, Sichuan Biokin Pharmaceutical (Biokin) announced that izalontamab brengitecan (iza-bren) had received approval for its second indication in China. The approval covers adults with recurrent or metastatic esophageal squamous cell carcinoma whose disease had progressed following treatment with a PD-1/PD-L1 inhibitor in combination with platinum-based chemotherapy.

Iza-bren simultaneously targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), delivering a topoisomerase I (TOP1) inhibitor payload. The approval was based on positive findings from the Phase 3 PANKU-Esophagus01 trial, which met both its PFS and OS primary endpoints.

These developments add to the evidence supporting ADCs across different cancer types and treatment settings, while creating opportunities for broader therapeutic applications.

Novel Payloads: Expanding the Mechanisms of Action of Targeted Therapies

As more ADCs enter clinical use, overcoming resistance and improving the therapeutic window have become important priorities. During the third quarter, several acquisitions and licensing agreements highlighted efforts to move beyond conventional ADC payloads by incorporating mechanisms such as enzyme inhibition, signaling pathway blockade, and targeted protein degradation.

On July 6, Novartis announced an agreement to acquire Myricx Bio for $1.1 billion upfront and up to $400 million in potential milestone payments. The acquisition, completed on August 28, gave Novartis access to Myricx Bio's ADC platform featuring N-myristoyltransferase inhibitor (NMTi) payloads.

N-myristoyltransferase (NMT) catalyzes the myristoylation of proteins, a lipid modification involved in regulating protein function. Unlike commonly used TOP1 inhibitor payloads, NMT inhibitors may exert antitumor effects by disrupting this process. In preclinical studies, Myricx Bio's candidates demonstrated antitumor activity in certain models resistant to TOP1 inhibitors, suggesting a potential approach to addressing resistance to existing ADC payloads.

On August 28, Genentech, a member of the Roche Group, entered a global collaboration with DualityBio to develop next-generation ADCs using DualityBio's novel-payload DUPAC platform. Under the agreement, DualityBio will receive $45 million upfront and is eligible for more than $1 billion in potential milestone payments.

The DUPAC platform includes several payload classes, including DUP5, DUP9, and DUP10. DUP5 inhibits eukaryotic translation initiation factor eIF4A, disrupting protein synthesis in cancer cells. DUP9, a derivative of lurbinectedin, interferes with RNA polymerase II-mediated transcription and induces DNA damage. Preclinical studies reported in 2025 showed that ADCs incorporating DUP5 or DUP9 demonstrated antitumor activity in certain tumor models that responded poorly to DXd-based ADCs.

The platform also supports dual-payload ADC development. For example, at the 2026 American Association for Cancer Research (AACR) Annual Meeting, DualityBio presented preclinical findings for DB-1326, a TA-MUC1-targeted ADC incorporating both a TOP1 inhibitor and DUP9 payload. The candidate demonstrated promising antitumor activity in preclinical tumor models.

Another collaboration explored the combination of small-molecule signaling pathway inhibitors with antibody-mediated delivery.

On September 3, HUTCHMED entered a licensing agreement with GSK for HMPL-A830, receiving $110 million upfront and becoming eligible for up to $1.185 billion in additional milestone payments. HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that combines a KRAS inhibitor payload with an EGFR-targeting antibody. The candidate is designed to deliver a KRAS inhibitor to EGFR-expressing tumors, combining antibody-mediated tumor targeting and EGFR signaling inhibition with the pharmacological activity of the KRAS inhibitor payload. At the time of the announcement, a Phase 1 trial was expected to begin in the second half of 2026. Unlike conventional cytotoxic ADCs, this approach explores how antibody-mediated delivery can be combined with small-molecule pathway inhibition.

Targeted protein degradation is another emerging direction in conjugate therapeutics. On July 29, Johnson & Johnson announced the completion of its $1 billion acquisition of Firefly Bio, gaining access to the company's Firelink degrader-antibody conjugate (DAC) platform. The platform uses antibodies to deliver selective protein degraders into target cells, with the goal of degrading disease-associated proteins while limiting exposure in healthy tissues. Johnson & Johnson plans to explore the technology for solid tumors, including those driven by KRAS alterations.

From NMT inhibitors and KRAS inhibitors to targeted protein degraders, researchers are exploring how antibody-mediated delivery can be applied to an increasingly diverse range of payload mechanisms.

Radioligand Therapies: Earlier Treatment and Accelerating Industry Consolidation

Radioligand therapy represents another important area of conjugate therapeutics. Unlike ADCs, which rely on chemical payloads, radioligand therapies combine targeting molecules with radionuclides, using radiation emitted by the radionuclide to kill cancer cells.

On July 31, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with androgen receptor pathway inhibitor (ARPI) therapy for patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, a disease category previously referred to as metastatic hormone-sensitive prostate cancer.

The approval was based on the Phase 3 PSMAddition trial, which enrolled 1,144 patients and met its primary radiographic progression-free survival (rPFS) endpoint, with an HR of 0.72 (95% CI: 0.58–0.90). Pluvicto was previously approved for metastatic castration-resistant prostate cancer. The new indication extends its use to an earlier treatment setting.

Meanwhile, radioligand development is expanding beyond tumor-cell targets to components of the tumor microenvironment.

On July 20, Immunome announced that the first patient had been dosed in a Phase 1 trial of IM-3050, a fibroblast activation protein (FAP)-targeted lutetium-177 radioligand therapy. IM-3050 targets cancer-associated fibroblasts (CAFs) within the tumor microenvironment. It is designed to deliver radioactivity to tumor regions and potentially damage nearby cancer cells through crossfire irradiation. The ongoing study will evaluate safety, dosimetry, pharmacokinetics (PK), and preliminary antitumor activity.

In addition to clinical progress, the radiopharmaceutical sector saw several major transactions during the quarter. On August 3, Curium and Lantheus announced a definitive merger agreement, with total consideration to Lantheus shareholders of up to approximately $8 billion. The proposed transaction aims to combine the companies' radiopharmaceutical diagnostic and therapeutic portfolios, development pipelines, and global manufacturing networks to strengthen drug development and supply capabilities.

On September 21, Telix and ITM announced a strategic merger agreement. ITM has established production capabilities for therapeutic radioisotopes, including lutetium-177, actinium-225, and terbium-161, as well as radiopharmaceutical candidates such as ITM-11, which has completed Phase 3 clinical development. The proposed combination would bring together Telix's clinical pipeline and commercialization capabilities with ITM's isotope production and supply infrastructure.

On September 22, BoomRay also announced an exclusive global licensing agreement with Novartis involving a preclinical radioligand therapy asset. The agreement includes upfront and potential milestone payments totaling up to $900 million. These developments illustrate how progress in radioligand therapies depends not only on clinical evidence but also on reliable isotope production, manufacturing, and distribution capabilities.

Precision Targeting and Conditional Activation: Improving Payload Delivery to Tumors

While the payload determines a conjugate's pharmacological activity, target recognition, cellular uptake, and local drug release influence where those effects occur. Compared with conventional monospecific ADCs, bispecific ADCs targeting two distinct antigens may bind to tumor cells with different antigen expression profiles. By optimizing target engagement and cellular internalization, these designs could also improve payload delivery. Beyond iza-bren, discussed earlier, additional bispecific ADC candidates are advancing through clinical development.

On August 3, Pathos AI entered a licensing agreement with a subsidiary of Alphamab Oncology for JSKN016. Under the agreement, Pathos AI secured development and commercialization rights outside Greater China, with an upfront payment of $125 million and up to $2.093 billion in potential milestone payments.

JSKN016 is a TROP2/HER3-targeted bispecific ADC that uses glycosite-specific conjugation to achieve a homogeneous drug-to-antibody ratio (DAR) of 4. The candidate is designed to deliver a TOP1 inhibitor payload following binding to TROP2 and/or HER3 and subsequent cellular internalization. A Phase 3 trial in triple-negative breast cancer is underway.

Multispecific targeting strategies are not limited to antibodies. On September 9, TwoStep Therapeutics announced the completion of a $62.5 million Series A financing round, along with FDA clearance of the investigational new drug (IND) application for TS-104, its multispecific peptide-drug conjugate. TS-104 uses a targeting peptide capable of binding five tumor-associated integrins and is conjugated to the cytotoxic payload monomethyl auristatin E (MMAE). By recognizing multiple tumor-associated targets, the candidate aims to reduce dependence on high expression of a single antigen and improve drug delivery across tumors with heterogeneous antigen expression.

In contrast to multispecific targeting, conditionally activated conjugates seek to control payload release by exploiting biological characteristics of the tumor microenvironment.

On September 16, Avacta reported preliminary results from the Phase 1 FOCUS-01 trial of AVA6103, an FAP-activated peptide-drug conjugate. The candidate is designed to use FAP-associated enzymatic activity to trigger the release of its exatecan payload in specific biological environments.

Based on initial safety and PK data from 19 patients across the first three dose levels, researchers observed sustained payload release consistent with the proposed mechanism, with release continuing for several days after administration. These findings provide early clinical evidence supporting the platform's proposed mechanism of action.

Together, these strategies highlight the importance of looking beyond target selection alone. Effective conjugate design also requires an understanding of how payloads enter target cells, when they are released, and whether payload release is appropriately matched to the intended mechanism of action.

As conjugate therapeutics become increasingly complex, developing linkers, payloads, and other small-molecule building blocks is becoming more demanding. Beyond designing novel payloads and linkers with tailored release properties, researchers must address complex synthesis, structural characterization, purification and scale-up, and the safe handling of highly potent compounds.

WuXi AppTec RCS has established a comprehensive ADC linker-payload synthesis platform, designed to support the growing demand for highly specialized cytotoxic conjugation components in next-generation targeted therapies. Built upon more than a decade of experience in complex small-molecule and high-potency chemistry, the platform integrates customized linker-payload synthesis, analytical characterization, and safe handling capabilities into a flexible and scalable workflow. Supported by a team of over 580 experienced chemists, RCS has delivered more than 27,000 compounds and accumulated extensive expertise across diverse linker-payload chemistries, enabling partners to efficiently advance ADC programs from early discovery through development. The platform provides access to a highly modular linker–payload toolbox comprising over 1,000 linkers, more than 30 antibody attachment sites, and over 30 novel payloads and analogs.

RCS supports a broad spectrum of cytotoxic payload classes, including camptothecins, auristatins, maytansinoids, pyrrolobenzodiazepines (PBD), and duocarmycins, alongside a well-established modular building-block warehousing system featuring hundreds of linker and payload intermediates. This infrastructure allows rapid material supply, often transferring compounds from warehouse to laboratory within 4 hours. Meanwhile, the RCS platform supports synthesis scales ranging from milligrams to hundreds of grams, facilitated by advanced analytical and purification capabilities, including LC-MS/HPLC, CAD/ELSD detection, high-field NMR, Prep-HPLC-MS, and Prep-SFC-MS. These tools enable efficient impurity identification, challenging separations, and precise structural validation, particularly for unstable or weakly UV-active linker-payload molecules.

Complementing technical expertise, RCS has dedicated high-potency laboratories equipped with isolators, strict containment protocols, and comprehensive personnel protection procedures to ensure safe and compliant handling of cytotoxic compounds. By combining modular chemistry design, scalable synthesis, advanced analytics, and robust safety infrastructure, WuXi AppTec RCS provides partners with an integrated and reliable solution for ADC linker-payload development, accelerating the creation of innovative conjugate therapeutics with enhanced efficiency and confidence.

Looking Ahead

In Q3 2026, conjugate therapeutics advanced on both clinical and technological fronts. Positive Phase 3 results for B7-H3-targeted ADCs, together with the expansion of ADCs and radioligand therapies into earlier treatment settings, provided further evidence of the therapeutic potential of these modalities. At the same time, novel payloads, multispecific targeting strategies, and conditionally activated delivery technologies created new opportunities for drug development.

These advances are also placing new demands on molecular design, synthesis, analytical characterization, manufacturing, and clinical development. WuXi AppTec will continue to leverage its integrated, end-to-end CRDMO platform to help global partners accelerate the development of more innovative conjugate therapeutics and bring more precise and effective therapies to patients.

參考資料:

各公司官網

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。